HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. (Q27853242)

13 November 2016

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Adrian Lee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Bing Yu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jamie E Chaft

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Mark G Kris

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

3

Sandra O'Toole

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Wendy Cooper

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Maria E Arcila

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Nick Pavlakis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

29 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

90

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

617-619

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

29 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4724317

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4724317

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4724317

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4724317

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4724317

Lung cancer: intragenic ERBB2 kinase mutations in tumours

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4724317

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4724317

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4724317

10.1016/J.LUNGCAN.2015.10.025

27 November 2018

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26559459%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

PubMed publication ID

26559459

2 references